

Luca Gattinoni

List of Publications by Citations

Source: <https://exaly.com/author-pdf/8253292/luca-gattinoni-publications-by-citations.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

110
papers

15,750
citations

58
h-index

115
g-index

115
ext. papers

18,446
ext. citations

13.5
avg, IF

6.1
L-index

#	Paper	IF	Citations
110	A human memory T cell subset with stem cell-like properties. <i>Nature Medicine</i> , 2011 , 17, 1290-7	50.5	1153
109	Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. <i>Journal of Experimental Medicine</i> , 2005 , 202, 907-12	16.6	809
108	Adoptive immunotherapy for cancer: building on success. <i>Nature Reviews Immunology</i> , 2006 , 6, 383-93	36.5	724
107	Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. <i>Journal of Clinical Investigation</i> , 2005 , 115, 1616-26	15.9	701
106	Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005 , 102, 9571-6	11.5	692
105	Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells. <i>Nature Medicine</i> , 2009 , 15, 808-13	50.5	675
104	Tumor-specific Th17-polarized cells eradicate large established melanoma. <i>Blood</i> , 2008 , 112, 362-73	2.2	615
103	Inhibiting glycolytic metabolism enhances CD8+ T cell memory and antitumor function. <i>Journal of Clinical Investigation</i> , 2013 , 123, 4479-88	15.9	535
102	IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004 , 101, 1969-74	11.5	441
101	Paths to stemness: building the ultimate antitumour T cell. <i>Nature Reviews Cancer</i> , 2012 , 12, 671-84	31.3	376
100	CD8+ T-cell memory in tumor immunology and immunotherapy. <i>Immunological Reviews</i> , 2006 , 211, 214-24	24.3	369
99	Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling. <i>Journal of Clinical Investigation</i> , 2007 , 117, 2197-204	15.9	365
98	IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy. <i>Blood</i> , 2008 , 111, 5326-33	2.2	320
97	Th17 cells are long lived and retain a stem cell-like molecular signature. <i>Immunity</i> , 2011 , 35, 972-85	32.3	316
96	Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009 , 106, 17469-74	11.5	302
95	BACH2 represses effector programs to stabilize T(reg)-mediated immune homeostasis. <i>Nature</i> , 2013 , 498, 506-10	50.4	264
94	T memory stem cells in health and disease. <i>Nature Medicine</i> , 2017 , 23, 18-27	50.5	234

93	The TCF1-Bcl6 axis counteracts type I interferon to repress exhaustion and maintain T cell stemness. <i>Science Immunology</i> , 2016 , 1,	28	233
92	High-efficiency transfection of primary human and mouse T lymphocytes using RNA electroporation. <i>Molecular Therapy</i> , 2006 , 13, 151-9	11.7	229
91	Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy. <i>Blood</i> , 2011 , 117, 808-14	2.2	226
90	Superior T memory stem cell persistence supports long-lived T cell memory. <i>Journal of Clinical Investigation</i> , 2013 , 123, 594-9	15.9	216
89	Akt inhibition enhances expansion of potent tumor-specific lymphocytes with memory cell characteristics. <i>Cancer Research</i> , 2015 , 75, 296-305	10.1	212
88	Mitochondrial Membrane Potential Identifies Cells with Enhanced Stemness for Cellular Therapy. <i>Cell Metabolism</i> , 2016 , 23, 63-76	24.6	210
87	MicroRNA-155 is required for effector CD8+ T cell responses to virus infection and cancer. <i>Immunity</i> , 2013 , 38, 742-53	32.3	204
86	Determinants of successful CD8+ T-cell adoptive immunotherapy for large established tumors in mice. <i>Clinical Cancer Research</i> , 2011 , 17, 5343-52	12.9	204
85	Single-cell RNA-seq reveals TOX as a key regulator of CD8 T cell persistence in chronic infection. <i>Nature Immunology</i> , 2019 , 20, 890-901	19.1	198
84	Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells. <i>Journal of Immunotherapy</i> , 2010 , 33, 1-7	5	197
83	Sorting through subsets: which T-cell populations mediate highly effective adoptive immunotherapy?. <i>Journal of Immunotherapy</i> , 2012 , 35, 651-60	5	195
82	Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts. <i>Cancer Research</i> , 2010 , 70, 6725-34	10.1	187
81	Generation of clinical-grade CD19-specific CAR-modified CD8+ memory stem cells for the treatment of human B-cell malignancies. <i>Blood</i> , 2016 , 128, 519-28	2.2	187
80	Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women. <i>Journal of Clinical Oncology</i> , 2005 , 23, 2155-61	2.2	178
79	Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8 T cells. <i>Journal of Clinical Investigation</i> , 2007 , 117, 492-501	15.9	155
78	Memory T cell-driven differentiation of naive cells impairs adoptive immunotherapy. <i>Journal of Clinical Investigation</i> , 2016 , 126, 318-34	15.9	152
77	Oxygen Sensing by T Cells Establishes an Immunologically Tolerant Metastatic Niche. <i>Cell</i> , 2016 , 166, 1117-1131.e14	56.2	151
76	Lineage relationship of effector and memory T cells. <i>Current Opinion in Immunology</i> , 2013 , 25, 556-63	7.8	139

75	Identification, isolation and in vitro expansion of human and nonhuman primate T stem cell memory cells. <i>Nature Protocols</i> , 2013 , 8, 33-42	18.8	138
74	Regulation of nucleosome landscape and transcription factor targeting at tissue-specific enhancers by BRG1. <i>Genome Research</i> , 2011 , 21, 1650-8	9.7	138
73	Repression of the DNA-binding inhibitor Id3 by Blimp-1 limits the formation of memory CD8+ T cells. <i>Nature Immunology</i> , 2011 , 12, 1230-7	19.1	136
72	BACH2 regulates CD8(+) T cell differentiation by controlling access of AP-1 factors to enhancers. <i>Nature Immunology</i> , 2016 , 17, 851-860	19.1	136
71	Wnt/beta-catenin signaling in T-cell immunity and cancer immunotherapy. <i>Clinical Cancer Research</i> , 2010 , 16, 4695-701	12.9	123
70	A novel chimeric antigen receptor against prostate stem cell antigen mediates tumor destruction in a humanized mouse model of pancreatic cancer. <i>Human Gene Therapy</i> , 2014 , 25, 1003-12	4.8	113
69	Transcriptional repressor ZEB2 promotes terminal differentiation of CD8+ effector and memory T cell populations during infection. <i>Journal of Experimental Medicine</i> , 2015 , 212, 2027-39	16.6	108
68	Effective tumor treatment targeting a melanoma/melanocyte-associated antigen triggers severe ocular autoimmunity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008 , 105, 8061-6	11.5	105
67	Development of replication-defective lymphocytic choriomeningitis virus vectors for the induction of potent CD8+ T cell immunity. <i>Nature Medicine</i> , 2010 , 16, 339-45	50.5	102
66	Toll-like receptors in tumor immunotherapy. <i>Clinical Cancer Research</i> , 2007 , 13, 5280-9	12.9	101
65	Vaccine-stimulated, adoptively transferred CD8+ T cells traffic indiscriminately and ubiquitously while mediating specific tumor destruction. <i>Journal of Immunology</i> , 2004 , 173, 7209-16	5.3	100
64	TCF1 Is Required for the T Follicular Helper Cell Response to Viral Infection. <i>Cell Reports</i> , 2015 , 12, 2099-1106	11.6	97
63	Inhibition of AKT signaling uncouples T cell differentiation from expansion for receptor-engineered adoptive immunotherapy. <i>JCI Insight</i> , 2017 , 2,	9.9	94
62	Retinoic acid controls the homeostasis of pre-cDC-derived splenic and intestinal dendritic cells. <i>Journal of Experimental Medicine</i> , 2013 , 210, 1961-76	16.6	93
61	Inhibition of Akt signaling promotes the generation of superior tumor-reactive T cells for adoptive immunotherapy. <i>Blood</i> , 2014 , 124, 3490-500	2.2	87
60	Cish actively silences TCR signaling in CD8+ T cells to maintain tumor tolerance. <i>Journal of Experimental Medicine</i> , 2015 , 212, 2095-113	16.6	85
59	miR-155 augments CD8+ T-cell antitumor activity in lymphoreplete hosts by enhancing responsiveness to homeostatic β cytokines. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015 , 112, 476-81	11.5	80
58	Extrathymic generation of tumor-specific T cells from genetically engineered human hematopoietic stem cells via Notch signaling. <i>Cancer Research</i> , 2007 , 67, 2425-9	10.1	78

57	Modulating the differentiation status of ex vivo-cultured anti-tumor T cells using cytokine cocktails. <i>Cancer Immunology, Immunotherapy</i> , 2013 , 62, 727-36	7.4	71
56	Lineage relationship of CD8(+) T cell subsets is revealed by progressive changes in the epigenetic landscape. <i>Cellular and Molecular Immunology</i> , 2016 , 13, 502-13	15.4	70
55	T cells genetically engineered to overcome death signaling enhance adoptive cancer immunotherapy. <i>Journal of Clinical Investigation</i> , 2019 , 129, 1551-1565	15.9	69
54	Genetic engineering of murine CD8+ and CD4+ T cells for preclinical adoptive immunotherapy studies. <i>Journal of Immunotherapy</i> , 2011 , 34, 343-52	5	65
53	Programming CD8+ T cells for effective immunotherapy. <i>Current Opinion in Immunology</i> , 2006 , 18, 363-70.8	7.8	59
52	Lactate dehydrogenase inhibition synergizes with IL-21 to promote CD8 T cell stemness and antitumor immunity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020 , 117, 6047-6055	11.5	57
51	Two subsets of stem-like CD8 memory T cell progenitors with distinct fate commitments in humans. <i>Nature Immunology</i> , 2020 , 21, 1552-1562	19.1	57
50	The transcription factor c-Myb regulates CD8 T cell stemness and antitumor immunity. <i>Nature Immunology</i> , 2019 , 20, 337-349	19.1	57
49	T-cell receptor gene therapy of established tumors in a murine melanoma model. <i>Journal of Immunotherapy</i> , 2008 , 31, 1-6	5	54
48	Ezh2 phosphorylation state determines its capacity to maintain CD8 T memory precursors for antitumor immunity. <i>Nature Communications</i> , 2017 , 8, 2125	17.4	53
47	Pharmacologic induction of CD8+ T cell memory: better living through chemistry. <i>Science Translational Medicine</i> , 2009 , 1, 11ps12	17.5	52
46	CTLA-4 dysregulation of self/tumor-reactive CD8+ T-cell function is CD4+ T-cell dependent. <i>Blood</i> , 2006 , 108, 3818-23	2.2	51
45	Antioxidant metabolism regulates CD8+ T memory stem cell formation and antitumor immunity. <i>JCI Insight</i> , 2018 , 3,	9.9	49
44	Moving T memory stem cells to the clinic. <i>Blood</i> , 2013 , 121, 567-8	2.2	48
43	ONC201 kills breast cancer cells by targeting mitochondria. <i>Oncotarget</i> , 2018 , 9, 18454-18479	3.3	45
42	Bedside to bench and back again: how animal models are guiding the development of new immunotherapies for cancer. <i>Journal of Leukocyte Biology</i> , 2004 , 76, 333-7	6.5	42
41	In vitro generated anti-tumor T lymphocytes exhibit distinct subsets mimicking in vivo antigen-experienced cells. <i>Cancer Immunology, Immunotherapy</i> , 2011 , 60, 739-49	7.4	40
40	The transcription factor BACH2 promotes tumor immunosuppression. <i>Journal of Clinical Investigation</i> , 2016 , 126, 599-604	15.9	39

39	miR-155 harnesses Phf19 to potentiate cancer immunotherapy through epigenetic reprogramming of CD8 T cell fate. <i>Nature Communications</i> , 2019 , 10, 2157	17.4	36
38	Th17 cells are refractory to senescence and retain robust antitumor activity after long-term ex vivo expansion. <i>JCI Insight</i> , 2017 , 2, e90772	9.9	36
37	Adoptive transfer of allogeneic tumor-specific T cells mediates effective regression of large tumors across major histocompatibility barriers. <i>Blood</i> , 2008 , 112, 4746-54	2.2	32
36	Transcriptional regulation of effector and memory CD8+ T cell fates. <i>Current Opinion in Immunology</i> , 2013 , 25, 321-8	7.8	26
35	Programming tumor-reactive effector memory CD8+ T cells in vitro obviates the requirement for in vivo vaccination. <i>Blood</i> , 2009 , 114, 1776-83	2.2	26
34	Transcriptional profiles reveal a stepwise developmental program of memory CD8(+) T cell differentiation. <i>Vaccine</i> , 2015 , 33, 914-23	4.1	25
33	Prognostic significance of cancer-testis gene expression in resected non-small cell lung cancer patients. <i>Oncology Reports</i> , 2004 , 12, 145-51	3.5	24
32	Enhancing adoptive T cell immunotherapy with microRNA therapeutics. <i>Seminars in Immunology</i> , 2016 , 28, 45-53	10.7	23
31	AKT-inhibition facilitates generation of polyfunctional stem cell memory-like CD8 T cells for adoptive immunotherapy. <i>Oncolimmunology</i> , 2018 , 7, e1488565	7.2	23
30	BACH2 enforces the transcriptional and epigenetic programs of stem-like CD8 T cells. <i>Nature Immunology</i> , 2021 , 22, 370-380	19.1	23
29	Type I cytokines synergize with oncogene inhibition to induce tumor growth arrest. <i>Cancer Immunology Research</i> , 2015 , 3, 37-47	12.5	22
28	CXCR3 Identifies Human Naive CD8 T Cells with Enhanced Effector Differentiation Potential. <i>Journal of Immunology</i> , 2019 , 203, 3179-3189	5.3	21
27	Memory T cells officially join the stem cell club. <i>Immunity</i> , 2014 , 41, 7-9	32.3	18
26	Identification of the genomic insertion site of Pmel-1 TCR α and β transgenes by next-generation sequencing. <i>PLoS ONE</i> , 2014 , 9, e96650	3.7	17
25	Reply to: Ectenin does not regulate memory T cell phenotype. <i>Nature Medicine</i> , 2010 , 16, 514-515	50.5	15
24	An engineered IL-2 partial agonist promotes CD8 T cell stemness. <i>Nature</i> , 2021 , 597, 544-548	50.4	14
23	Renal Cancer Treatment: A Review of the Literature. <i>Tumori</i> , 2003 , 89, 476-484	1.7	13
22	Short-term effects of anastrozole treatment on insulin-like growth factor system in postmenopausal advanced breast cancer patients. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2002 , 80, 411-8	5.1	9

21	Lineage relationship of CD8+ T cell subsets is revealed by progressive changes in the epigenetic landscape. <i>Cellular and Molecular Immunology</i> , 2015 ,	15.4	7
20	The dark side of T memory stem cells. <i>Blood</i> , 2015 , 125, 3519-20	2.2	6
19	CD8(+) T lymphocytes isolated from renal cancer patients recognize tumour cells through an HLA- and TCR/CD3-independent pathway. <i>Cancer Immunology, Immunotherapy</i> , 2007 , 56, 1065-76	7.4	6
18	Prognostic significance of cancer-testis gene expression in resected non-small cell lung cancer patients. <i>Oncology Reports</i> , 2004 , 12, 145	3.5	6
17	The short and sweet of T-cell therapy: Restraining glycolysis enhances the formation of immunological memory and antitumor immune responses. <i>Oncolmmunology</i> , 2014 , 3, e27573	7.2	4
16	Unusual aspects of melanoma. Case 2. Regionally advanced nasal cavity melanoma. <i>Journal of Clinical Oncology</i> , 2004 , 22, 745-6	2.2	4
15	miR-155 releases the brakes on antitumor T cells. <i>Oncolmmunology</i> , 2015 , 4, e1026533	7.2	3
14	Stubborn Tregs limit T-cell therapy. <i>Blood</i> , 2012 , 120, 2352-4	2.2	2
13	Renal cancer treatment: a review of the literature. <i>Tumori</i> , 2003 , 89, 476-84	1.7	2
12	141 The Role of T Memory Stem Cells. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012 , 59, 59	3.1	1
11	Identification of tumor antigen-specific cytotoxic T lymphocytes cross-recognizing allogeneic major histocompatibility class I molecules. <i>Tissue Antigens</i> , 2000 , 56, 19-29		1
10	Cancer cells hijack T-cell mitochondria. <i>Nature Nanotechnology</i> , 2021 ,	28.7	1
9	The New Old CD8+ T Cells in the Immune Paradox of Pregnancy. <i>Frontiers in Immunology</i> , 2021 , 12, 765780	8.4	1
8	Harnessing Stem Cell-Like Memory T Cells for Adoptive Cell Transfer Therapy of Cancer. <i>Cancer Drug Discovery and Development</i> , 2015 , 183-209	0.3	1
7	International Regensburg Center for Interventional Immunology (RCI) symposium on "Synthetic immunology and environment-adapted redirection of T cells", 17-18 July, 2019, Regensburg, Germany. <i>Cancer Immunology, Immunotherapy</i> , 2020 , 69, 677-682	7.4	
6	T memory stem cell formation: Caveat mTOR. <i>EBioMedicine</i> , 2016 , 4, 3-4	8.8	
5	Could exemestane affect insulin-like growth factors, interleukin 6 and bone metabolism in postmenopausal advanced breast cancer patients after failure on aminoglutethimide, anastrozole or letrozole? 2003 , 22, 1081		
4	Partly MHC Matched Allogeneic Tumor Specific T Cells Mediate Tumor Regression without Inducing GVHD in Immunosuppressed Host.. <i>Blood</i> , 2006 , 108, 5210-5210	2.2	

- 3 Transcriptional repressor ZEB2 promotes terminal differentiation of CD8+ effector and memory T cell populations during infection. *Journal of Cell Biology*, **2015**, 211, 2113OIA259 7.3
- 2 Treatment of Large Established Murine Melanoma with Th17 Polarized CD4+ T Helper Cells Genetically Engineered to Express MHC Class II Restricted T Cell Receptor. *Blood*, **2008**, 112, 3911-3911 2.2
- 1 Akt Signalling Inhibition Promotes The Ex Vivo generation Of Minor Histocompatibility Antigen-Specific CD8+ Memory Stem T Cells. *Blood*, **2013**, 122, 3269-3269 2.2